Hospital UV-C footprint Surfacide has a proven track record with over 600 hospital, long-term care, and public venue deployments, highlighting strong credibility for selling to hospitals and care facilities seeking proven infection prevention technology.

Strategic partnerships Ongoing collaborations with MedStar Health, PathTrac, Fidelis Sustainability Distribution, and iCleanse indicate a healthy partner ecosystem that can be leveraged to access new accounts, expand channel reach, and accelerate purchasing decisions.

Expanded solutions Product launches such as SURFrx, GLŌ PX, and Eos portable UV-C devices demonstrate a diversified product portfolio across room decontamination, low-level disinfection programs, and portable solutions ideal for clusters of high-traffic spaces, enabling cross-sell to varying facility needs.

Security and compliance Being FDA-authorized and designed for hospital-grade disinfection positions Surfacide as a trusted, compliant provider, appealing to procurement teams prioritizing regulatory alignment and objective evidence of efficacy.

Growth signals Revenue range and scalable manufacturing in Wisconsin, plus a global deployment footprint, suggest capacity to support larger deals with multiple facilities, as well as potential for enterprise deals with health systems aggressively pursuing enhanced infection prevention.